Sarepta (SRPT) Q2 Earnings Miss, DMD Drugs' Sales Robust

This article was originally published on Nasdaq

Sarepta Therapeutics, Inc. SRPT reported a loss of $2.65 per share for the second quarter of 2022, wider than the Zacks Consensus Estimate of a loss of $1.07 per share. The loss was also wider than the year-ago loss of $1.02 per share.